In addition to FDA-approved agents targeting sensitive alterations in EGFR, ALK, ROS1, BRAF, MET, RET and NTRK, the precision therapeutic arsenal in NSCLC may soon expand to other oncogenic drivers, including previously-cited KRAS G12C (13% of all NSCLC) [196] and HER2 exon 20 mutations [146] lending further credence to the necessity of molecular profiling in this target-rich disease. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.